Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | F7 | P08709 | 1/20 | 0.41 |
| ▸ | F3 | P13726 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.39 |
| ▸ | GABRE | P78334 | 1/20 | 0.39 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7233246 | 0.84 | HTT (0.51) | MEN1KMT2AMAPTCA9CA12 | |
| SCHEMBL7227233 | 0.80 | NPC1 (0.44) | MEN1KMT2AMAPTCA9CA12 | |
| SCHEMBL6718661 | 0.77 | AR (0.55) | MEN1KMT2AMAPTF7F3 | |
| SCHEMBL12113006 | 0.74 | MAPT (0.71) | MEN1KMT2AMAPTCA9CA12 | |
| SCHEMBL13742980 | 0.73 | CA12 (0.46) | MEN1KMT2AMAPTCA9CA12 | |
| SCHEMBL5332842 | 0.72 | MAPT (0.63) | MEN1KMT2AMAPTCA9CA12 | |
| SCHEMBL6647679 | 0.71 | CA9 (0.49) | MEN1KMT2AMAPTF7F3 | |
| SCHEMBL7224180 | 0.71 | AR (0.37) | CA9CA12ALDH1A1RAB9APOLB | |
| SCHEMBL6720509 | 0.69 | CA9 (0.56) | MEN1KMT2AMAPTCA9CA12 | |
| SCHEMBL4736404 | 0.69 | MAPT (0.42) | MEN1KMT2AMAPTCA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6593480-B2 | Obesity, hyperglycemia | ABBOTT LABORATORIES | 2003-07-15 | — | — | US | disclosed |
| WO-2002070507-A2 | GLYCORTICOID RECEPTOR ANTAGONISTS FOR TREATMENT OF DIABETES | ABBOTT LABORATORIES (US) | 2002-09-12 | — | — | WO | disclosed |
| US-6329534-B1 | USEFUL FOR THERAPY OF TYPE II DIABETES, OBESITY, HYPERGLYCEMIA, INADEQUATE GLUCOSE CLEARANCE, HYPERINSULINEMIA, HYPERTRIGLYCERIDEMIA, AND HIGH-CIRCULATING GLUCOCORTICOID LEVELS | ABBOTT LABORATORIES | 2001-12-11 | — | — | US | disclosed |
| US-20010041802-A1 | Glucocorticoid receptor antagonists for treatment of diabetes | KARO BIO AB (SE) | 2001-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041802-A1 | Glucocorticoid receptor antagonists for treatment of diabetes | NR3C1, GPR119, NR3C2 | MEN1 3785/4885KMT2A 4048/4885MAPT 4638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.